Wyden bills seek transparency from drug companies and PBMs

Aiming to increase transparency of drug prices, Senate Finance Committee Ranking Member Ron Wyden (D-Ore.) introduced a trio of bills Wednesday, including two that would make manufacturer price hikes and PBM negotiations public information.

The Stopping the Pharmaceutical Industry from Keeping Drugs

Read the full 412 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE